NOVARTIS on the successful authorization for the commercialization of its products, including the design and execution of a strategy to maintain the condition that these are recognized as reference and innovator products, and not as therapeutic equivalents, as intended by the authority in the first place. Also, on obtaining and safeguarding regulatory data protection (Data Exclusivity) of its innovative products.